The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dorken, B.
Right arrow Articles by Nadler, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dorken, B.
Right arrow Articles by Nadler, L. M.

The Journal of Immunology, Vol 136, Issue 12 4470-4479, Copyright © 1986 by American Association of Immunologists

ARTICLES

HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes

B Dorken, G Moldenhauer, A Pezzutto, R Schwartz, A Feller, S Kiesel and LM Nadler

The B cell-restricted antigen HD39, whose cell surface expression is limited to resting and activated human B lymphocytes, is described in this report. The monoclonal antibody HD39 detects a two-chain glycoprotein with apparent molecular weights of 130,000 and 140,000. During B cell ontogeny, HD39 is first expressed in the cytoplasm of bone marrow derived pre-B cells, then appears on the cell surface of sIgM+ B cells, and finally on the majority of sIgM+ sIgD+ resting B cells. After activation in vitro, the expression of HD39 on the cell surface first increases, and then the antigen is lost as cells begin to differentiate. HD39 is weakly expressed on very few non-T cell ALL and B cell CLL, on approximately 50% of B cell lymphomas, and not on Waldenstrom's macroglobulinemias and myelomas. In contrast, it is strongly expressed on all hairy cell leukemias. Its limited cell surface expression in B cell ontogeny suggests that HD39 may be important in the events that regulate the activation of the human resting B lymphocytes.


This article has been cited by other articles:


Home page
 BloodHome page
J. Zhang, A. Raper, N. Sugita, R. Hingorani, M. Salio, M. J. Palmowski, V. Cerundolo, and P. R. Crocker
Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors
Blood, May 1, 2006; 107(9): 3600 - 3608.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
A. Varki and T. Angata
Siglecs--the major subfamily of I-type lectins
Glycobiology, January 1, 2006; 16(1): 1R - 27R.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Leonard, M. Coleman, J. Ketas, M. Ashe, J. M. Fiore, R. R. Furman, R. Niesvizky, T. Shore, A. Chadburn, H. Horne, et al.
Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma
J. Clin. Oncol., August 1, 2005; 23(22): 5044 - 5051.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, R. Furman, M. W. Schuster, E. J. Feldman, M. Ashe, S. J. Schuster, W. A. Wegener, et al.
Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin's Lymphoma: Phase I/II Clinical Trial Results
Clin. Cancer Res., August 15, 2004; 10(16): 5327 - 5334.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Carnahan, P. Wang, R. Kendall, C. Chen, S. Hu, T. Boone, T. Juan, J. Talvenheimo, S. Montestruque, J. Sun, et al.
Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22: Characterization of in Vitro Properties
Clin. Cancer Res., September 1, 2003; 9(10): 3982S - 3990.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, S. Ely, R. R. Furman, W. A. Wegener, H. J. Hansen, H. Ziccardi, M. Eschenberg, et al.
Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin's Lymphoma
J. Clin. Oncol., August 15, 2003; 21(16): 3051 - 3059.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. N. Damle, F. Ghiotto, A. Valetto, E. Albesiano, F. Fais, X.-J. Yan, C. P. Sison, S. L. Allen, J. Kolitz, P. Schulman, et al.
B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes
Blood, May 13, 2002; 99(11): 4087 - 4093.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Mandik-Nayak, G. Huang, K. C. F. Sheehan, J. Erikson, and D. D. Chaplin
Signaling Through TNF Receptor p55 in TNF-{alpha}-Deficient Mice Alters the CXCL13/CCL19/CCL21 Ratio in the Spleen and Induces Maturation and Migration of Anergic B Cells into the B Cell Follicle
J. Immunol., August 15, 2001; 167(4): 1920 - 1928.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Floyd, J. Ni, A. L. Cornish, Z. Zeng, D. Liu, K. C. Carter, J. Steel, and P. R. Crocker
Siglec-8. A NOVEL EOSINOPHIL-SPECIFIC MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY
J. Biol. Chem., January 14, 2000; 275(2): 861 - 866.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Nicoll, J. Ni, D. Liu, P. Klenerman, J. Munday, S. Dubock, M.-G. Mattei, and P. R. Crocker
Identification and Characterization of a Novel Siglec, Siglec-7, Expressed by Human Natural Killer Cells and Monocytes
J. Biol. Chem., November 26, 1999; 274(48): 34089 - 34095.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
L. Mandik-Nayak, S.-j. Seo, C. Sokol, K. M. Potts, A. Bui, and J. Erikson
MRL-lpr/lpr Mice Exhibit a Defect in Maintaining Developmental Arrest and Follicular Exclusion of Anti-double-stranded DNA B Cells
J. Exp. Med., June 7, 1999; 189(11): 1799 - 1814.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
T. L. O'Keefe, G. T. Williams, F. D. Batista, and M. S. Neuberger
Deficiency in CD22, a B Cell-specific Inhibitory Receptor, Is Sufficient to Predispose to Development of High Affinity Autoantibodies
J. Exp. Med., April 19, 1999; 189(8): 1307 - 1313.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. L. Cornish, S. Freeman, G. Forbes, J. Ni, M. Zhang, M. Cepeda, R. Gentz, M. Augustus, K. C. Carter, and P. R. Crocker
Characterization of Siglec-5, a Novel Glycoprotein Expressed on Myeloid Cells Related to CD33
Blood, September 15, 1998; 92(6): 2123 - 2132.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Hennet, D. Chui, J. C. Paulson, and J. D. Marth
Immune regulation by the ST6Gal sialyltransferase
PNAS, April 14, 1998; 95(8): 4504 - 4509.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
L. Mandik-Nayak, A. Bui, H. Noorchashm, A. Eaton, and J. Erikson
Regulation of Anti-double-stranded DNA B Cells in Nonautoimmune Mice: Localization to the T-B Interface of the Splenic Follicle
J. Exp. Med., October 20, 1997; 186(8): 1257 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. D. Powell and A. Varki
I-type Lectins
J. Biol. Chem., June 16, 1995; 270(24): 14243 - 14246.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. D. Powell, R. K. Jain, S. Sabesan, and A. Varki
Characterization of Sialyloligosaccharide Binding by Recombinant Soluble and Native Cell-associated CD22
J. Biol. Chem., March 31, 1995; 270(13): 7523 - 7532.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Hanasaki, A. Varki, and L. D. Powell
CD22-mediated Cell Adhesion to Cytokine-activated Human Endothelial Cells
J. Biol. Chem., March 31, 1995; 270(13): 7533 - 7542.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
R. Schulte, M. Campbell, W. Fischer, and B. Sefton
Tyrosine phosphorylation of CD22 during B cell activation
Science, November 6, 1992; 258(5084): 1001 - 1004.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1986 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1986 by The American Association of Immunologists, Inc. All rights reserved.